Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC). The phase III international VISION trial found that treatment with a novel form of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, in combination with standard-of-care treatment, led to an increase in radiographic progression-free survival (rPFS) and overall survival (OS).
↧